Answers are grounded in this paper and cite their sources.
Endometriosis is a chronic, estrogen-dependent, inflammatory and fibrotic disease characterized by endometrial-like tissue outside the uterine cavity. Although retrograde menstruation explains the presence of endometrial fragments in the peritoneal cavity, it does not explain why only a subset of women develop persistent lesions, chronic pain or infertility. Increasing evidence indicates that endometriosis emerges from a permissive immunological and microbial ecosystem in which ectopic cells evade clearance, induce angiogenesis and neurogenesis, remodel extracellular matrix and sustain chronic inflammation. Immune abnormalities include macrophage expansion and M2-like polarization, impaired natural killer cell cytotoxicity, tolerogenic dendritic cells, altered neutrophil and mast-cell activity, Th17/Treg imbalance, exhausted cytotoxic T cells, B-cell activation and autoantibody production. In parallel, microbial dysbiosis in the gut, vagina, cervix, endometrium and peritoneal cavity may influence lesion biology through lipopolysaccharide/TLR4 activation, increased intestinal permeability, estrogen recycling by the estrobolome, short-chain fatty acid depletion, altered bile acid and tryptophan metabolism, and modulation of macrophage, NK-cell and T-cell phenotypes. This review explored the bidirectional immune-microbiota interactions that may drive the implantation, survival and progression of endometriotic lesions. We propose an “immune-microbial endocrine loop” in which dysbiosis amplifies inflammation and estrogenic signaling, while endometriotic lesions reshape local and systemic microbial niches. This paradigm has implications for current treatments. Hormonal suppression reduces estrogenic stimulation and symptoms but may not fully correct immune-microbial drivers. Surgery removes visible lesions but cannot necessarily reset the inflammatory microbiome or prevent recurrence. Revisiting hormonal and surgical strategies through an immune-microbial lens supports adjunctive approaches such as perioperative microbiome profiling, anti inflammatory nutrition, probiotics, postbiotics, selective antibiotics, estrobolome modulation, macrophage/ NK-cell-targeted therapy and personalized postoperative suppression. Robust longitudinal human studies and mechanism-based trials are required before microbiome-directed interventions can be routinely integrated into care.
No takes yet. Share an insight, caveat, or question.
Rad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: